Miglustat API Manufacturers

compare suppliers & get competitive offers

Filters

Reset

Selected filters:

Type
Production region
Qualifications
Country of origin

Produced in:

Unknown

Established in: 1963

MOQ: -

Employees: 800+

World’s 1st exclusive API distributor

Portfolio of 600+ APIs

>250 clients in Europe

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

  • MSDS

Contact supplier

Replies quickly

Located in:

Malta
  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

Contact supplier

Replies slower than most

Located in:

Italy
  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Miglustat API 72599-27-0?

Description:
Here you will find a list of producers, manufacturers and traders of Miglustat. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Miglustat 
Synonyms:
BuDNJ , Butyldeoxynojirimycin , Miglustatum , N-Butylmoranoline , NB-dnj , Zavesca  
Cas Number:
72599-27-0 
DrugBank number:
DB00419 
Unique Ingredient Identifier:
ADN3S497AZ

About Miglustat

More information about the use of: Miglustat. Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase.

Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea. Miglustat was first developed as an anti-HIV agent in the 1990s. However, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect.

Check who is selling Miglustat in the overview above.

Miglustat is a type of Glycosides


Glycosides are a prominent subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the development of various drugs and medicines. These compounds are characterized by the presence of a glycosidic bond, which connects a sugar molecule (glycone) to a non-sugar component (aglycone). Glycosides have gained significant attention in the pharmaceutical industry due to their diverse biological activities and therapeutic potential. They are widely used as natural sources for drug discovery and development. Many plants produce glycosides, and these natural compounds exhibit a wide range of pharmacological effects, such as anti-inflammatory, anticancer, antimicrobial, and antioxidant properties.

The extraction and isolation of glycosides from natural sources require specialized techniques like chromatography, solvent extraction, and purification methods. Once isolated, glycosides undergo rigorous testing and evaluation to determine their safety, efficacy, and dosage requirements.

Pharmaceutical companies utilize glycosides in the formulation of various medications, including cardiovascular drugs, anticancer agents, and anti-diabetic medications. Glycosides also serve as precursors for the synthesis of other pharmaceutical compounds, contributing to the development of new drugs and therapies.

As research in the field of glycosides continues to advance, scientists are exploring their potential applications in drug delivery systems, bioavailability enhancement, and targeted drug delivery. These innovative approaches aim to optimize the therapeutic benefits of glycosides and improve patient outcomes.

In conclusion, glycosides are a vital subcategory of pharmaceutical APIs, offering immense potential for drug development and therapeutic applications. Continued research and exploration of glycosides are crucial for expanding our understanding of their properties and unlocking their full pharmaceutical potential.


Miglustat (Glycosides), classified under Cardiac stimulants


Cardiac stimulants are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of cardiac disorders. These medications are designed to enhance the functioning of the heart by stimulating its electrical impulses and increasing its contractility.

Cardiac stimulants work by targeting specific receptors in the heart, promoting the release of neurotransmitters such as norepinephrine and epinephrine. These neurotransmitters bind to adrenergic receptors, leading to an increased heart rate and force of contraction, which helps improve cardiac output.

One commonly used cardiac stimulant API is Dobutamine. Dobutamine acts primarily on beta-1 adrenergic receptors in the heart, increasing the strength of cardiac contractions while minimizing the impact on heart rate. This makes it a valuable medication in cases of acute heart failure or during cardiac stress testing.

Another well-known cardiac stimulant API is Isoproterenol. Isoproterenol acts on both beta-1 and beta-2 adrenergic receptors, resulting in increased heart rate, contractility, and relaxation of the smooth muscles in the bronchi. It is commonly used in the treatment of bradycardia, heart block, and certain types of asthma.

Cardiac stimulant APIs play a vital role in cardiovascular medicine and are often used in emergency situations or as temporary measures to improve heart function. However, it is important to note that their use requires careful monitoring and should be administered under medical supervision due to potential side effects such as increased blood pressure, arrhythmias, and myocardial ischemia.

In conclusion, cardiac stimulant APIs are a critical category of pharmaceutical ingredients used to enhance heart function. Medications like Dobutamine and Isoproterenol act on specific receptors in the heart, leading to increased contractility and heart rate. While these medications provide important therapeutic benefits, their use should be closely monitored by medical professionals due to potential side effects.



Miglustat manufacturers | traders | suppliers

We have 3 companies offering Miglustat produced in 3 different countries.

Get in contact with the supplier of your choice:

  • TIEFENBACHER API + Ingredients from Germany, product country of origin Unknown
  • Amino Chemicals from Malta, product country of origin Malta
  • Dipharma Francis S.r.l. from Italy, product country of origin Italy

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.